Baseline characteristics of patients with AL cardiac amyloidosis.

Zadok, Osnat Itzhaki Ben; Vaturi, Mordehay; Vaxman, Iuliana; Iakobishvili, Zaza; Rhurman-Shahar, Noa; Kornowski, Ran; Hamdan, Ashraf

doi:10.1371/journal.pone.0255487.s003

pone.0255487.s003.docx (19.13 kB)

Baseline characteristics of patients with AL cardiac amyloidosis.

journal contribution

posted on 2021-08-09, 17:40 authored by Osnat Itzhaki Ben Zadok, Mordehay Vaturi, Iuliana Vaxman, Zaza Iakobishvili, Noa Rhurman-Shahar, Ran Kornowski, Ashraf Hamdan

Data are presented as medians (25^th, 75^th quartiles) or as percentages, as appropriate. ^ Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. Journal of clinical oncology 2012;30(9):989–95. Nine (29%) patients had missing NT-proBNP levels at baseline, thus precluding the calculation of cardiac prognostic stage. ^# Palladini G, Hegenbart U, Milani P, Kimmich C, Foli A, Ho AD, et al. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood. 2014;124(15):2325–32. Eight (26%) patients had missing urine-24 hour protein assessment at baseline, thus precluding the calculation of renal stage. Abbreviations: AL, immunoglobulin light-chain.

(DOCX)